Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJLSG1901 pembrolizumab plus pemetrexed in elderly metastatic non-squamous NSCLC with PD-L1 TPS <50%
jRCTs041200012Phase 2Completed
- Sponsor
- MSD
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and pemetrexed in Non-small cell lung cancer (NS-NSCLC), sponsored by MSD. Primary endpoint: Overall response rate. Started Jul 2020; status: completed.
02
Drugs
pembrolizumabpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs041200012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200012.